PCA3 in prostate cancer and tumor aggressiveness detection on 407 high-risk patients: a National Cancer Institute experience

BACKGROUND: Prostate cancer (PCa) is the most common male cancer in Europe and the US. The early diagnosis relies on prostate specific antigen (PSA) serum test, even if it showed clear limits. Among the new tests currently under study, one of the most promising is the prostate cancer gene 3 (PCA3),...

Descripción completa

Detalles Bibliográficos
Autores principales: Merola, Roberta, Tomao, Luigi, Antenucci, Anna, Sperduti, Isabella, Sentinelli, Steno, Masi, Serena, Mandoj, Chiara, Orlandi, Giulia, Papalia, Rocco, Guaglianone, Salvatore, Costantini, Manuela, Cusumano, Giuseppe, Cigliana, Giovanni, Ascenzi, Paolo, Gallucci, Michele, Conti, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324853/
https://www.ncbi.nlm.nih.gov/pubmed/25651917
http://dx.doi.org/10.1186/s13046-015-0127-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4324853/
https://www.ncbi.nlm.nih.gov/pubmed/25651917
http://dx.doi.org/10.1186/s13046-015-0127-8

Ejemplares similares